Old Web
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
2009
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
35
References
56
Citations
NaN
KQI